JERUSALEM--(BUSINESS WIRE)--July 17, 2006--BioLineRx, Ltd., Israel's leading drug development company, announced today that it has signed an exclusive worldwide licensing agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, for the development and commercialization of BL-3020, a novel orally-available peptide for the treatment of obesity. Financial terms of the license were not disclosed.
